CB2 Regulation Did Not Follow a Simple Kinase-Recruitment Rule in Cells
Adding regulatory kinases did not substantially increase CB2 arrestin recruitment in an engineered-cell study. A familiar receptor-regulation model was not automatically applicable to this cannabinoid receptor.
Real-time cellular measurements
Researchers used CB2-expressing HEK293 cells and BRET assays to assess arrestin movement and G-protein signaling. They varied kinase expression and mutated selected receptor residues. These were in-vitro measurements, not animal behavior or patient tolerance.
Negative and positive findings differed
Overexpressing the tested GRK isoforms failed to produce a substantial recruitment enhancement, and inhibiting endogenous GRK2/3 did not substantially suppress arrestin translocation. Mutating C-terminal aspartic-acid residues, however, reduced arrestin recruitment and signaling desensitization.
The model suggests rather than settles
The results supported a possible phospho-mimic role for those residues. Engineered receptor abundance and the host-cell environment limit transfer to native tissues. A null kinase effect does not prove that phosphorylation never matters, nor does short-term desensitization directly measure clinical cannabis tolerance. The paper provides a testable regulatory mechanism while cautioning against importing CB1 or other receptor assumptions wholesale into CB2 biology.
Related analysis: Cannabis Tolerance Claims: Questions to Ask Before Relying on Expert Testimony.
Primary research
Delineating the interactions between the cannabinoid CB2 receptor and its regulatory effectors; β-arrestins and GPCR kinases. British journal of pharmacology (2022). DOI: 10.1111/bph.15748.
